<DOC>
	<DOCNO>NCT00003498</DOCNO>
	<brief_summary>RATIONALE : Antineoplastons naturally-occurring substance may also make laboratory . Antineoplastons may inhibit growth cancer cell . PURPOSE : This phase II trial study well antineoplaston therapy work treat patient non-Hodgkin 's lymphoma respond high-dose chemotherapy bone marrow transplantation .</brief_summary>
	<brief_title>Antineoplaston Therapy Treating Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety possible effectiveness antineoplastons A10 AS2-1 patient non-Hodgkin 's lymphoma fail high-dose chemotherapy bone marrow transplantation . - Describe response , tolerance , side effect regimen patient . OUTLINE : This open-label study . Patients receive gradually escalate dos intravenous antineoplaston A10 antineoplaston AS2-1 6 time per day maximum tolerate dose reach . Treatment continue least 12 month absence disease progression unacceptable toxicity . After 12 month , patient respond stable disease may continue treatment . Tumors measure every 8 week 6 month , every 3 month 2 year , every 6 month year 3 4 , annually year 5 6 . PROJECTED ACCRUAL : A total 20-40 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove nonHodgkin 's disease fail prior highdose chemotherapy bone marrow transplantation PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : At least 2 month Hematopoietic : WBC great 2,000/mm^3 Platelet count great 20,000/mm^3 Hepatic : Bilirubin great 2.5 mg/dL Renal : Creatinine great 2.5 mg/dL No history renal condition contraindicate high dosage sodium Cardiovascular : No hypertension No history congestive heart failure No history cardiovascular condition contraindicate high dosage sodium Other : Not pregnant nursing Fertile patient must use effective contraception 4 week study participation No serious active infection PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy recover No concurrent immunomodulatory agent ( e.g. , interferon interleukin2 ) Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosoureas ) recover Endocrine therapy : At least 4 week since prior corticosteroid No concurrent corticosteroid Radiotherapy : At least 8 week since prior radiotherapy recover Surgery : Not specify Other : No prior antineoplaston therapy No concurrent antineoplastic agent No concurrent antibiotic , antifungal , antiviral</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>